ENLV earnings: next report 2026-09-04, real EPS beat/miss history, analyst consensus Buy, P/E 0.01. Updated 2026-07-23.
Enlivex Therapeutics (ENLV) Research Hub
Enlivex Therapeutics (ENLV) trades on NASDAQ, IL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.9595 USD (-7.74%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 0.01, market cap 0.08B. This hub links to the full technical, earnings and options research available for ENLV.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IL |
| Last close | 0.9595 USD (-7.74%) |
| 52-week range | 0.9595 USD – 10.61 USD |
| Trend regime | Range |
| 14-day RSI | 13.6 (Oversold) |
| Trailing P/E | 0.01 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-04 |
Available research for ENLV
Covered Call on ENLV: how it works, illustrative setup around the real 0.9595 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ENLV: how it works, illustrative setup around the real 0.9595 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ENLV: how it works, illustrative setup around the real 0.9595 USD price, max profit/loss, breakeven and when to use it. Educational.
ENLV technical analysis: range, last 0.9595 USD, RSI 13.6, 52w range 0.9595 USD–10.61 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ENLV in?
Enlivex Therapeutics (ENLV) is classified under Healthcare (Biotechnology), listed on NASDAQ, IL.
Is ENLV in an uptrend or downtrend?
As of 2026-09-11, ENLV is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ENLV's trailing P/E ratio?
ENLV's trailing P/E is 0.01, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does ENLV next report earnings?
ENLV is next scheduled to report earnings on 2026-09-04, with a consensus EPS estimate of -0.3 USD.